Compare MNPR & GLAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNPR | GLAS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.4M | 504.2M |
| IPO Year | 2019 | 2021 |
| Metric | MNPR | GLAS |
|---|---|---|
| Price | $70.28 | $1.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $130.17 | $6.67 |
| AVG Volume (30 Days) | 127.0K | ★ 2.2M |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.52 |
| Revenue Next Year | N/A | $20.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $50.07 | $1.06 |
| 52 Week High | $124.82 | $12.70 |
| Indicator | MNPR | GLAS |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 24.25 |
| Support Level | $66.88 | $1.06 |
| Resistance Level | $75.33 | $2.81 |
| Average True Range (ATR) | 4.74 | 0.32 |
| MACD | 0.73 | 0.09 |
| Stochastic Oscillator | 51.81 | 8.50 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.